Таргетная терапия херувизма у ребенка 9 лет

Обложка

Цитировать

Полный текст

Об авторах

А. В. Лопатин

ФГАОУ ВО «Российский университет дружбы народов»

ORCID iD: 0000-0003-0043-9059
Россия

А. Ю. Кугушев

ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова»

Автор, ответственный за переписку.
Email: drkugushev@gmail.com
ORCID iD: 0000-0002-6881-7709

Кугушев Александр Юрьевич, канд. мед. наук, врач пластический хирург, детский хирург, отделение челюстно-лицевой хирургии РДКБ 

119571, Москва, Ленинский просп., 117 

Россия

С. А. Ясонов

ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова»

ORCID iD: 0000-0003-0319-3103
Россия

Список литературы

  1. Jaffe H.L. Giant-cell reparative granuloma, traumatic bone cyst, and fibrous (fibro-osseous) dysplasia of the jawbones. Oral Surg Oral Med Oral Pathol 6: 159; 1953.
  2. Hyckel P., Berndt A., Schleier P., Clement J.H., Beensen V., Peters H., Kosmehl H. Cherubism-new hypothesis on pathogenesis and therapeutic consequences. J Cranio-Maxillofac Surg 2005; 33 (1): 61–8.
  3. Lo B., Faiyaz-Ul-Haque M., Kennedy S., Aviv R., Tsui L.C., Teebi A.S. Novel mutation in the gene encoding c-Abl-binding protein SH3BP2 causes cherubism. Am J Med Genet A 2003; 121A (1): 37–40.
  4. Meng X.M., Yu S.F., Yu G.Y. Clinico-pathological study of 24 cases of cherubism. Int J Oral Max Surg 2005; 34 (4): 350–6.
  5. Anderson D.E., McClendon J.L. Cheru-bism-hereditary fibrous dysplasia of the jaws; I genetic considerations. Oral Surg Oral Med Oral Pathol 1962; 15 (Suppl 2): 5–16.
  6. Tiziani V., Reichenberger E., Buzzo C.L., Niazi S., Fukai N., Stiller M., Peters H., et al. The gene for cherubism maps to chromosome 4h16. Am J Hum Genet 1999; 65: 158–66.
  7. Ueki Y., Tiziani V., Santanna C., Fukai N., Maulik C., Garfinkle J., Ninomiya C., et al. Reichenberger E. Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet 2001; 28: 125–6.
  8. O'Connell J.E., Bowe C., Murphy C., Toner M., Kearns G.J. Aggressive giant cell lesion of the jaws: A review of management options and report of a mandibular lesion treated with denosumab. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 120: e191.
  9. Skubitz K.M., Cheng E.Y., Clohisy D.R., Thompson R.C., Skubitz A.P. Gene expression in giant-cell tumors. J Lab Clin Med 2004; 144: 193–200.
  10. Rutkowski P.I., Ferrari S., Grimer R.J., Stalley P.D., Dijkstra S.P., Pienkowski A., et al. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol 2015; 22 (9): 2860–8.
  11. Branstetter D.G., Nelson S.D., Manivel J.C., Blay J.Y., Chawla S., Thomas D.M., et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res 2012; 18: 4415–24.
  12. Karras N.A. Denosumab Treatment of Metastatic Giant-Cell Tumor of Bone in a 10-Year-Old Girl. J Clin Oncol 2013 Apr 20; 31 (12): e200–e202.
  13. Kobayashi E., Setsu N. Osteosclerosis induced by denosumab.Lancet 2015 Feb 7; 385 (9967): 539.
  14. Bredell M., Rordorf T., Kroiss S., Rücker M., Fritz Zweifel D., Rostetter C. Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study. J Oral Maxillofac Surg 2017: 1–10.
  15. Balke M., Ahrens H., Streitbuerger A., Koehler G., Winkelmann W., Gosheger G., Hardes J. Treatment options for recurrent giant cell tumors of bone. J Cancer Res Clin Oncol 2009; 135: 149–58.
  16. Thomas D., Henshaw R., Skubitz K., Chawla S., Staddon A., Blay J.Y., et al. Denosumab in patients with giant-cell tumour of bone: An openlabel, phase 2 study. Lancet Oncol 2010; 11: 275–80.
  17. Lipton A., Jacobs I. Denosumab: Benefits of RANK ligand inhibition in cancer patients. Curr Opin Support Palliat Care 2011; 5: 258–64.
  18. Rostetter C., Rordorf T., Essig H., Zweifel D., Schumann P., Rücker M., Bredell M. New approach to treatment of giant granula with denosumab. A case example. Swiss Dent J 2017; 127: 520 (in German).
  19. Tarsitano A., Del Corso G., Pizzigallo A., Marchetti C. Aggressive central giant cell granuloma of the mandible treated with conservative surgical enucleation and interferon-alpha-2a: Complete remission with long-term follow-up. J Oral Maxillofac Surg 2015; 73: 2149.
  20. Naidu A., Malmquist M.P., Denham C.A., Schow S.R. Management of central giant cell granuloma with subcutaneous denosumabtherapy. J Oral Maxillofac Surg 2014; 72: 2469.
  21. Schreuder W.H., Coumou A.W., Kessler P.A., de Lange J. Alternative pharmacologic therapy for aggressive central giant cell granuloma:Denosumab. J Oral Maxillofac Surg 2014; 72: 1301.
  22. Gupta B., Stanton N., Coleman H., White C., Singh J. A novel approach to the management of a central giant cell granuloma with denosumab: A case report and review of current treatments. J Craniomaxillofac Surg 2015; 43: 1127.
  23. Pham Dang N., Longeac M., Picard M., Devoize L., Barthélémy I. Central giant cell granuloma in children: Presentation of different therapeutic options.Rev Stomatol Chir Maxillofac Chir Orale 2016; 117: 142 (in French).
  24. Skubitz K.M. Giant cell tumor of bone: current treatment options. Curr Treat Options Oncol 2014; 15: 507.
  25. Ruggiero S.L., Dodson T.B., Fantasia J., Goodday R., Aghaloo T., Mehrotra B., O'Ryan F. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw – 2014 Update. J Oral Maxillofac Surg 2014; 72: 1938.
  26. Saad D., Saad P. Report of a jaw osteonecrosis possibly caused by denosumab. Eur J Oral Implantol 2017;10 (2): 213–22.
  27. Demirel F., Esen I., Tunc B., Tavil B. Scarcity despite wealth: Osteopetrorickets. J Pediatr Endocrinol Metab 2010; 23: 931–4.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Лопатин А.В., Кугушев А.Ю., Ясонов С.А., 2018

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.